Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.
Eur J Pharmacol. 2011 Dec 30;673(1-3):65-9. doi: 10.1016/j.ejphar.2011.10.012. Epub 2011 Oct 21.
The aim of this study was to characterize the α₁-adrenoceptor subtype(s) involved in the noradrenaline-induced contraction of retinal arterioles in rats. In vivo ocular fundus images were captured with a digital camera equipped with a special objective lens. By measuring changes in diameter of retinal arterioles in the fundus images, retinal vascular response was assessed. The systemic blood pressure and heart rate in the animals were also continuously recorded. Following blockade of β₁/β₂-adrenoceptors with propranolol, noradrenaline (0.03-3 μg/kg/min, i.v.) decreased the diameter of retinal arterioles and increased the mean blood pressure in a dose-dependent manner. The highest dose (3 μg/kg/min, i.v.) of noradrenaline caused a small increase in heart rate. The α(1A)-adrenoceptor antagonist RS100329 (0.1 mg/kg, i.v.) and the α(1D)-adrenoceptor antagonist BMY 7378 (1 mg/kg, i.v.) significantly prevented noradrenaline-induced contraction of retinal arterioles and pressor responses whereas the α(1B)-adrenoceptor antagonist L-765314 (1 mg/kg, i.v.) did not. The α(1A)-adrenoceptor agonist, A 61603 (0.03-0.3 μg/kg/min, i.v.), also caused contractile responses of retinal arterioles and pressor responses. These responses were almost completely prevented by RS100329 (0.1 mg/kg, i.v.), but not by BMY 7378 (1 mg/kg, i.v.). These results suggest that the contractile effects of noradrenaline on retinal arterioles and peripheral resistance vessels are, at least in part, mediated by stimulation of α(1A)- and α(1D)-adrenoceptors. Furthermore, it is likely that the α₁-adrenoceptor subtype(s) involved in rat vascular responses are similar in both retinal and peripheral circulation.
本研究旨在描述参与去甲肾上腺素诱导大鼠视网膜小动脉收缩的 α₁-肾上腺素受体亚型。使用配备特殊物镜的数码相机捕获眼底的活体图像。通过测量眼底图像中视网膜小动脉的直径变化,评估视网膜血管反应。同时连续记录动物的系统血压和心率。在阻断β₁/β₂-肾上腺素受体后,去甲肾上腺素(0.03-3μg/kg/min,静脉内)以剂量依赖性方式降低视网膜小动脉的直径并增加平均血压。最高剂量(3μg/kg/min,静脉内)的去甲肾上腺素引起心率的轻微增加。α(1A)-肾上腺素受体拮抗剂 RS100329(0.1mg/kg,静脉内)和 α(1D)-肾上腺素受体拮抗剂 BMY 7378(1mg/kg,静脉内)显著预防去甲肾上腺素诱导的视网膜小动脉收缩和升压反应,而 α(1B)-肾上腺素受体拮抗剂 L-765314(1mg/kg,静脉内)则没有。α(1A)-肾上腺素受体激动剂 A 61603(0.03-0.3μg/kg/min,静脉内)也引起视网膜小动脉收缩和升压反应。这些反应几乎完全被 RS100329(0.1mg/kg,静脉内)预防,但不能被 BMY 7378(1mg/kg,静脉内)预防。这些结果表明,去甲肾上腺素对视网膜小动脉和外周阻力血管的收缩作用至少部分是通过刺激 α(1A)-和 α(1D)-肾上腺素受体介导的。此外,参与大鼠血管反应的 α₁-肾上腺素受体亚型在视网膜和外周循环中可能相似。